Orizuru is an R&D driven company focusing on the development of iPS cell-based regenerative medicine and the application of iPS cell technologies. The company was established in 2021 to translate the outcomes of T-CiRA, a joint research program established by
Orizuru plans to accelerate the clinical development and manufacturing of innovative regenerative medicine products using iPS cell-derived cardiomyocytes (iCMs) for severe chronic heart failure patients and iPS cell-derived pancreatic islet cells (iPICs) for brittle type 1 diabetes patients.
NSPI expects Orizuru to achieve medium-term growth as it allocates capital efficiently and implements new therapies using iPS cell technologies.
This material has been prepared by
This material is not intended to solicit or recommend the purchase or sale of any specific securities, and nothing in this material is intended to suggest or guarantee future investment results or returns.
This material has been prepared based on information deemed reliable, but NSPI does not guarantee the accuracy or completeness of the information. The contents of this material is based on information prior to the preparation of this material and may not be relied upon in the future. The contents of this material are subject to change without prior notice.
NSPI's investment strategy and other asset management services provided by NSPI (the 'NSPI Services') mainly invest in stocks and other securities. However, the principal amount invested in stocks and other securities is not guaranteed, and there is a risk that the value of the stocks and other securities invested in may fluctuate due to the bankruptcy of the issuing company or changes in its business performance or financial conditions, or due to changes in economic and social conditions inside or outside
With respect to the NSPI Services, you may be required to pay prescribed fees, remuneration and expenses (the 'Fee'). The Fee to be borne by you will be determined according to the content of services provided, so the amount and calculation method of such Fee cannot be stated in advance.
For details of risks and the Fee pertaining to individual NSPI Services, please refer to the contents of documents such as the prospectus and the product brochure delivered in connection with individual NSPI Services.
Please read the prospectus, product brochures and other documents delivered in relation to individual NSPI Services carefully before entering into an actual transaction, and make sure to do so based on your own judgment and responsibility.
Trade name:
Financial Instruments Business Operator, Director-General of the
Membership:
About This English News Release
The contents of this material are based on an English translation of a Japanese announcement made on
Please note that the information contained in this material is for reference purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities by NSPI to any person in
Furthermore, none of the funds in this material have been or will be registered under the United States Securities Act of 1933, as amended ('1933 Act'), or under the securities laws of any state or political subdivision of
Accordingly, the information in this material is not made or directed to any person in
Furthermore, the information in this material is not made or directed to any person in the
(C) 2024 Electronic News Publishing, source